EGFR and cancer: Osimertinib, a third‐generation of EGFR TKI, induced higher CD47 expression in EGFRmut NSCLC HCC827 and NCI‐H1975 cells via NF‐κB signaling, and it also reduced PD‐L1 expression in cancer cells.